Fudan University

This study tests a personalized vaccine (Neo-DC) made from a patient's own immune cells to target specific cancer markers. It is for people aged 18-75 with advanced solid tumors who have not responded to standard treatments. The goal is to check safety and see if the vaccine can …

This study tests a new drug (HRS-4642) combined with an immunotherapy (adebrelimab) and other anti-cancer agents in people with advanced pancreatic cancer that has not responded to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or…

This study tests two drugs together—MRG003 and pucotenlimab—for people with a rare and aggressive type of thyroid cancer (ATC or PDTC) that has spread and cannot be removed by surgery. About 60 adults will receive the combination every three weeks. The main goal is to see if the …

This study tests a combination of an immune-boosting drug (TQB2450) and a high-dose hormone (progestin) to treat young women (ages 18-45) with a specific type of early-stage endometrial cancer (MMRd). The goal is to eliminate the cancer while preserving the uterus so patients can…

This study looks at whether adding chemotherapy to radiation therapy after surgery helps prevent thymic cancer from coming back. About 172 adults who had their tumor fully removed will receive either radiation alone or radiation plus four cycles of chemotherapy. Participants will…

This study tests whether a combination of two hormone drugs (GnRHa and letrozole) works better than standard hormone pills (megestrol or medroxyprogesterone) for treating early-stage endometrial cancer while preserving the ability to have children. About 104 women with stage I, l…

This study tests two experimental drugs, SHR-0302 and SHR-2554, given together to people with a rare type of blood cancer called peripheral T-cell lymphoma that has returned or not improved after prior treatment. The goal is to see if the combination is safe and can shrink or con…

This study tests whether adding a targeted chemotherapy (R-CDOP) plus a spinal injection of methotrexate can prevent central nervous system relapse in people with high-risk diffuse large B-cell lymphoma. About 83 adults who have not yet been treated will receive this combination.…

This study tests a drug called tunlametinib in people with advanced melanoma that has a specific genetic change (NRAS mutation) and has not responded to previous treatments. The goal is to see if the drug can shrink tumors and control the disease. About 110 adults will take the d…

This study tests whether adding a CDK4/6 inhibitor to standard hormone therapy can help prevent breast cancer from returning in people with a high-risk type called HR+/HER2+. About 1,900 participants who have already completed initial treatment will be followed for 5 years. The g…

This study tests whether adding immunotherapy to a precise type of radiation (that spares key lymph nodes) and standard chemotherapy can better control advanced esophageal cancer. About 432 adults with squamous cell carcinoma will receive either the triple therapy or radiation pl…

This study is for people with high-risk stage III colorectal cancer. It tests whether using a blood test (ctDNA) to guide treatment decisions can improve outcomes. Participants will receive either standard chemotherapy or chemotherapy plus bevacizumab, with regular blood monitori…

This study tests whether two drugs, sacituzumab tirumotecan and bevacizumab, can shrink or control brain tumors in people with triple-negative breast cancer that has spread to the brain. About 24 adults with this condition will receive the combination and be monitored for tumor r…

This study aims to improve fertility-sparing treatment for young women with endometrial cancer by using the tumor's genetic profile to choose the best therapy. About 260 participants will receive treatments matched to their cancer subtype, such as hormone therapy or immunotherapy…

This study looks at whether metformin, a common diabetes medicine, can improve mild memory problems in older adults who are overweight or obese. About 54 people aged 60-75 will take metformin or a placebo for 26 weeks, along with lifestyle advice. The goal is to see if metformin …

This study tests a treatment plan for people with low rectal cancer that can be removed with surgery. Participants receive chemotherapy and an immunotherapy drug called tislelizumab before surgery. The goal is to see if this combination can make the cancer disappear completely, a…

This study tests whether adding immunotherapy (a drug that helps the immune system fight cancer) after standard chemotherapy and radiation can help people with advanced esophageal cancer live longer without the disease getting worse. About 452 adults with a specific type of esoph…

This study looks at different second-line drug combinations for people with advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. Researchers want to see how well these treatments control the disease and what side effects occur. The study…

This study tests whether a new drug, serplulimab, combined with chemotherapy works better than the standard drug, nivolumab, plus chemotherapy for shrinking lung cancer before surgery. About 116 people with stage II to IIIa squamous non-small cell lung cancer will take part. The …

This study tests a mix of three treatments—chemotherapy (GEMOX), a targeted drug (donafenib), and an immunotherapy (tislelizumab)—in people with advanced bile duct cancer that has spread. The goal is to see if this combination shrinks tumors and improves survival. About 93 adults…

This study is for people with colorectal cancer that comes back within a year after finishing initial chemotherapy. It tests whether adding the drug serplulimab to standard second-line treatment can help control the cancer longer. About 40 participants will be randomly assigned t…

This study tests whether a combination of three drugs (RC48, sintilimab, and SOX) can shrink advanced stomach cancer enough to allow surgical removal. It is for 30 adults aged 18-70 with a specific type of stomach cancer (HER2 IHC 1+ or 2+) that cannot be removed initially. Parti…

This study tests whether matching treatment to the specific molecular subtype of triple-negative breast cancer can shrink tumors or slow progression in people whose cancer has not responded to prior therapies. About 120 women with advanced or metastatic disease will receive targe…

This study explores whether changes in a blood-based tumor marker (ctDNA) can help doctors decide the best treatment for people with HER2-negative metastatic breast cancer. Participants first receive a standard antibody-drug combination therapy. Based on how much the ctDNA level …

This study tests whether using an indoor air purifier can improve lung health in people with COPD. About 120 adults aged 50-80 who live in Shanghai will use either a real or fake air purifier at home. Researchers will measure changes in lung scans, breathing tests, and quality of…

This study is for people with HER2-negative breast cancer that has spread to the lining of the brain. It compares standard chemotherapy to standard chemotherapy plus a special type of chemotherapy delivered directly into the brain fluid through a small device called an Ommaya res…

This study tests a new surgical technique called Q-ISR for people with ultra-low rectal cancer. It compares Q-ISR to two standard surgeries to see if it can better preserve bowel function while still controlling the cancer. About 100 adults with small tumors near the anal opening…

This study is for people with a specific type of advanced lung cancer (EGFR-mutant) that has stopped responding to initial targeted pills. Researchers are testing whether adding targeted radiation to a four-drug combination (immunotherapy, anti-angiogenesis, and chemotherapy) can…

This study tests whether adding a liver-directed chemotherapy (HAIC) to a combination of two immunotherapy and anti-angiogenesis drugs (sintilimab plus bevacizumab biosimilar) can better control advanced liver cancer. About 164 adults with liver cancer that cannot be treated with…

This study tests whether adding tislelizumab to standard chemotherapy (liposomal doxorubicin and ifosfamide) can shrink tumors or slow growth in people with advanced soft tissue sarcoma that cannot be removed by surgery. About 45 adults aged 18 to 75 with specific sarcoma subtype…

This study tests a new approach for people with advanced breast, melanoma, or colorectal cancer that has spread to the liver. Doctors will use heat or cold to destroy some liver tumors, hoping this wakes up the immune system to fight cancer throughout the body. Then they add an i…

This phase 3 study compares an all-oral, chemotherapy-free drug combination (pyrotinib, trastuzumab subcutaneous, and dalpiciclib) against a standard chemo-containing regimen for advanced HER2-positive breast cancer. About 502 adults who have had at most one prior treatment for a…

This study is for women with early-stage breast cancer that has spread to 1 or 2 lymph nodes. It compares two radiation approaches: treating the whole lymph node area versus treating only the armpit area. The goal is to see if the smaller radiation area works just as well at prev…

This study tests whether adding the drug VEGFR BP102 to standard chemotherapy can help people with a specific subtype of advanced triple-negative breast cancer (called BLIS) live longer without their cancer growing. About 134 participants who have not had prior treatment for meta…

This study tests whether giving radiation only to the parts of the neck where cancer has spread works as well as treating the entire neck in people with nasopharyngeal carcinoma. About 462 adults with stage I–III disease will be randomly assigned to receive either standard or ind…

This study looks at whether a blood test that detects tumor DNA can help doctors decide which patients with early-stage colorectal cancer need stronger chemotherapy after surgery. About 80 patients whose blood tests show signs of remaining cancer one month after surgery will rece…

This study looks at whether a blood test that detects tumor DNA can help doctors decide how long chemotherapy should last for people with certain types of colorectal cancer. About 340 adults with stage II or low-risk stage III colorectal cancer will be assigned to either standard…

This study looks at whether giving a second course of antibody-drug conjugates (ADCs) can safely shrink tumors in people with advanced breast cancer who have already received these drugs. About 160 adults with metastatic breast cancer will receive the same or a different ADC and …

This study tests whether a transplant of donated umbilical cord blood can help people aged 14 to 80 with serious diseases caused by the Epstein-Barr virus (EBV), such as certain lymphomas or chronic active EBV infection. The goal is to control the disease and improve survival, bu…

This study tests whether adding a drug called narlumosbart and targeted radiation to standard chemotherapy and immunotherapy can improve treatment for advanced non-small cell lung cancer that has spread to the bones. The trial will enroll 27 adults who have not had prior treatmen…

This study tests whether adding two amino acid-based drugs (L-Ornithine L-Aspartate and N-Acetylcysteine) to standard hormone therapy can shrink tumors or slow disease in people with HR+/HER2- advanced breast cancer. About 40 women whose cancer progressed on prior treatments will…

This study tests two different treatment plans for people with locally advanced rectal cancer that has not spread. Both plans combine radiation, chemotherapy, an immunotherapy drug, and a pain reliever that may boost the immune response. The goal is to see which plan leads to a h…

This study tests whether adding radiotherapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (Toripalimab) can improve complete remission rates in people with locally advanced rectal cancer that is microsatellite stable. About 192 participants will be randomly …

This study looks at people with high-risk stage II colorectal cancer who have a positive blood test for cancer DNA one month after surgery. It aims to see if giving stronger chemotherapy based on that test can clear the cancer DNA and improve survival. About 340 participants will…

This study tests a drug called Becotatug vedotin in 40 adults with advanced liver cancer that has worsened after standard treatments. The goal is to see if it can shrink tumors and help control the disease. Participants receive the drug and are monitored for safety and response.

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) can help prevent stomach or gastroesophageal junction cancer from coming back after surgery. It includes 276 adults with high-risk or specific genetic types of cancer. Participants ar…

This study tests whether adding omega-3 fatty acids (EPA and DHA) to standard immunotherapy (PD-1 inhibitors) can improve muscle mass and treatment outcomes in adults with advanced esophageal cancer. About 142 participants will receive either omega-3 or a placebo for 6 months alo…

This study tests whether adding an antivascular drug to standard chemotherapy helps prevent breast cancer from returning after surgery. It is for women with a specific, aggressive type of triple-negative breast cancer. About 764 participants will be randomly assigned to receive e…

This study tests whether adding the drug cadonilimab (AK104) and radiation to standard chemotherapy helps people with colorectal cancer that has spread to the liver. About 73 adults who have not had treatment before will be randomly assigned to either the new combo or standard th…

This study tests a mix of several drugs (including sodium cromoglicate, choline, efavirenz, and others) combined with an immune checkpoint inhibitor in people with advanced triple-negative breast cancer whose tumors stopped responding to immunotherapy. The goal is to see if the c…

This study tests a mix of radiation, chemotherapy, immunotherapy, and targeted drugs in 44 people whose rectal cancer has returned after prior treatment. The goal is to shrink tumors enough for possible surgery. Participants receive focused radiation and up to 8 cycles of the dru…

This study tests whether combining radiation therapy with three drugs (platinum chemotherapy, adebrelimab, and bevacizumab) can control brain metastases from triple-negative breast cancer. About 58 adults aged 18-70 with this specific type of advanced breast cancer will receive t…

This study tests a combination of two drugs, fruquintinib and serplulimab, in people with advanced colorectal cancer that has not spread to the liver and has stopped responding to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. Re…

This study tests a new approach for people with high-risk soft tissue sarcoma that has not spread. Before surgery, patients receive a combination of radiation, chemotherapy, and an immunotherapy drug (sintilimab). The goal is to shrink the tumor enough to make surgery more effect…

This study tests whether the drug golidocitinib can help prevent peripheral T-cell lymphoma (a type of blood cancer) from returning after initial chemotherapy. It is for adults who have had a good response to their first treatment but cannot or choose not to have a stem cell tran…

This study tests whether adding retinoic acid to an immune checkpoint inhibitor can help shrink or control HER2-negative breast cancer that has stopped responding to prior immune therapy. About 10 adults with metastatic or advanced breast cancer will receive the combination treat…

This study looks at whether giving radiation therapy after surgery can help prevent thyroid cancer from coming back in people with a high risk of recurrence. About 80 adults with certain types of thyroid cancer will be followed for several years. The main goal is to see how long …

This study tests whether combining two drugs—sintilimab and chidamide—can help people with a rare type of lymphoma (peripheral T-cell lymphoma) that has returned or not responded to prior treatments. About 51 adults aged 18 to 75 will receive the drug combination. The goal is to …

This study tests whether adding probiotics (good bacteria) to standard chemoradiation and immunotherapy can help people with limited-stage small cell lung cancer live longer without the disease getting worse. About 60 adults aged 18-80 will take part. The goal is to see if this c…

This study tests a new drug (QL1706) combined with standard chemotherapy, with or without another drug (bevacizumab), as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination shrinks tumors or control…

This study tests a mix of three chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy drug (durvalumab) in people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and how safe it …

This study compares three different sequences of chemotherapy and radiation for people with early-stage natural killer/T-cell lymphoma, a rare and aggressive cancer. About 210 participants will be randomly assigned to one of three treatment plans. The goal is to see which approac…

This early study tests a new cell therapy called RGL-305 in 12 adults with lymphoma who still have signs of disease after standard treatment. The goal is to see if it is safe and how it works in the body. Researchers will monitor side effects and check if the therapy can reduce r…

This study looks at whether giving radiation therapy after completely removing a type of chest tumor called thymoma (stages II or III) helps prevent the cancer from coming back and improves survival. About 238 adults aged 18-75 who had surgery within the last 3 months will be ran…

This study tests whether adding radiotherapy to the usual radioactive iodine treatment helps prevent thyroid cancer from coming back in people with high-risk, advanced disease. About 124 adults who had surgery but still have some cancer left will be randomly assigned to get eithe…

This study tests whether adding a drug called IL-11 to the standard G-CSF can help blood cancer patients recover their blood cells faster after a stem cell transplant. About 224 adults with multiple myeloma or lymphoma will take part. The goal is to see if the combination reduces…

This study tests new drug combinations for people with advanced pancreatic cancer that has spread or cannot be removed. Researchers want to see if these targeted therapies are safe and shrink tumors. About 160 adults aged 18-75 with good organ function can join.

This study tests whether giving personalized chemotherapy before surgery (neoadjuvant therapy) can improve outcomes for people with early-stage breast cancer. Researchers will use detailed tumor typing to match each participant with the most promising drug combination. The trial …

This study tests two different radiation schedules (long-course vs short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 inhibitor), and a COX-2 inhibitor in people with a specific type of advanced rectal cancer (MSS type). The goal is to see which approac…

This study tests whether adding a special type of radiotherapy guided by a PET scan and an immunotherapy drug (cadonilimab) to standard second-line treatment can shrink tumors better than standard treatment alone in people with colorectal cancer that has spread to the abdomen. Ab…

This study tests whether a smaller, more targeted neck surgery (selective neck dissection) works as well as the standard larger surgery (modified neck dissection) for people with papillary thyroid cancer that has spread to only 1 or 2 small lymph nodes in the side of the neck. Ab…

This study tests several new drug combinations for people with advanced liver cancer (hepatocellular carcinoma) whose first treatment stopped working. About 350 adults will receive one of the experimental therapies, and researchers will use scans, blood tests, and tumor samples t…

This study tests whether adding an immunotherapy drug (anti-PD-1) to standard chemoradiation can better control anal squamous cell cancer and reduce the chance of it coming back. It includes 241 adults aged 18-75 with different stages of the disease, from early to advanced or rec…

This study tests a combination of two drugs, SKB264 and inetetamab, in people with advanced HER2-positive breast cancer whose disease got worse after treatment with T-DXd. The goal is to see if this new combination can shrink tumors. About 48 adults will take part in this single-…

This study tests whether adding a new drug (SHR-1701) to targeted radiation (SBRT) can slow the growth of advanced prostate cancer that no longer responds to hormone therapy. About 66 men with metastatic castration-resistant prostate cancer will be enrolled. The main goal is to s…

This early study tests two types of specially engineered immune cells (CAR-T and TCR-T) that target the Epstein-Barr virus (EBV) in patients with nasopharyngeal carcinoma that has come back or not responded to standard treatments. About 24 adults will receive one of the cell ther…

This study tests a daily pill called sunvozertinib in 34 people with advanced non-small cell lung cancer that has rare EGFR gene mutations. Participants have not had prior cancer treatment. The goal is to see if the drug shrinks tumors and delays cancer growth. This is a phase 2 …

This study tests a new drug called vebrekotuzumab, which delivers a powerful cancer-killing agent directly to tumor cells, for people with advanced esophageal cancer that no longer responds to initial treatment. About 104 participants will receive the drug either alone or with an…

This study looks at whether artificial intelligence can help detect breast cancer using standard chest CT scans that don't require a special dye. Researchers will compare the AI's accuracy to mammograms and breast MRIs in 5,000 women. The goal is to see if this approach could off…

This study aims to see if a new blood test can accurately identify the specific type of breast cancer a person has. Researchers will collect blood and tissue samples from 1500 people with advanced breast cancer. The goal is to compare the new test results with standard lab method…

This study aims to see if a stool test that looks for certain genetic markers in H. pylori bacteria, combined with a risk questionnaire, can detect stomach cancer earlier than current methods. Researchers will enroll 15,000 adults aged 40 and older. Participants will provide a st…

This study is testing a new, non-invasive way to screen for stomach cancer using a stool (poop) sample and a simple questionnaire. Researchers at Fudan University will enroll 15,000 adults aged 40 and older to see if the DNA test can find cancer earlier than current methods. Part…

This study checks if a tiny tissue sample taken during a scope (endoscopic biopsy) is as good as a larger sample from surgery for diagnosing stomach cancer. It looks at cancer type, grade, and key markers like HER-2 and MSI. The goal is to see if the less invasive biopsy can repl…

This study is testing a new blood test that looks at tiny pieces of DNA floating in the blood to find pancreatic neuroendocrine tumors early and tell them apart from other types of pancreatic tumors. Researchers will enroll 1,000 adults who have been diagnosed with certain pancre…

This study tests whether AI-assisted breast ultrasound and mammography can find breast cancer earlier than standard screening. About 16,000 women aged 35-69 will be split into two groups: one gets AI-assisted imaging, the other gets routine screening. The goal is to see if AI hel…

This study tests a skin protectant called Pinoxin to prevent skin injury caused by radiation therapy in cancer patients. About 202 adults with cancer who are starting radiation will be randomly assigned to receive either Pinoxin or a placebo cream. The main goal is to see if Pino…

This study tests a program called ICU-NO CRBSI to prevent catheter-related bloodstream infections in intensive care units. Researchers will track infection rates and how well healthcare workers follow infection-prevention practices. The study involves about 8,050 ICU patients acr…

This study tests whether limiting eating to a 10-hour window each day can lower the chance of developing gestational diabetes in pregnant women at high risk. Researchers will compare this approach to usual eating habits over 3 months in 240 women. The goal is to see if this simpl…

This study follows 300 Chinese patients with metastatic triple-negative breast cancer to see how their quality of life changes when taking sacituzumab govitecan or standard chemotherapy after first-line treatment fails. Researchers will measure symptoms and daily functioning usin…

This study tests whether corticosteroids can reduce hand-foot syndrome, a painful skin reaction caused by the chemotherapy drug liposomal doxorubicin. About 182 breast cancer patients will receive either high-dose, standard-dose, or no dexamethasone to see which works best. The g…

This study tests whether a tailored comfort care plan can help people with advanced esophageal cancer live longer and feel better. About 624 adults whose cancer has spread or returned and who are receiving immunotherapy will be randomly assigned to either precision palliative car…

This study tests whether wearing compression or ice gloves and socks can reduce nerve damage caused by the chemotherapy drug UTD1 in people with advanced breast cancer. About 324 participants will be randomly assigned to wear compression gloves/socks, ice gloves/socks, or no spec…

This study tests a digital mind-body therapy that uses music and biofeedback to help women with locally advanced breast cancer sleep better and feel less distressed during neoadjuvant treatment. About 66 participants will be randomly assigned to receive the digital therapy or sta…

This study looks at whether a new type of PET scan (TROP2-PET) can predict how well a targeted drug works in people with advanced HER2-negative breast cancer. About 45 participants will get both a standard and a TROP2-PET scan before starting treatment. The goal is to see if scan…

This study looks at whether a blood test that detects tumor DNA (ctDNA) can better track how well treatment is working and predict if cancer will come back in people with advanced colorectal cancer. About 500 participants will receive standard radiotherapy and chemotherapy, with …

This study is creating a large database of information from 2,000 people diagnosed with a rare pancreatic tumor called solid pseudopapillary neoplasm (SPN). The goal is to collect real-world data on how the disease progresses and how patients respond to treatment. This database w…

This study will follow 3000 people in China with peripheral T-cell lymphoma, a rare blood cancer, to see how they are treated in everyday practice and how well they do. Researchers will collect medical records and test samples to understand the disease better, find patterns, and …

This study is observing 1,000 adults who come to fever clinics with a respiratory infection. Researchers will collect information on symptoms, lab tests, and chest scans, then follow patients over time to see how they recover and if any complications arise. No experimental treatm…

This study looks at how the pain and sedation drug remifentanil behaves in low-weight patients in the intensive care unit who are on breathing machines. Researchers will measure drug levels in the blood and check vital signs like blood pressure. The goal is to find the right dose…

This study watches 150 adults with advanced liver cancer who are starting different types of immunotherapy for the first time. Researchers will measure how well the tumors shrink and how the immune system changes during treatment. The goal is to learn which immunotherapy works be…

This study will follow 2,500 people recently diagnosed with marginal zone B-cell lymphoma to learn more about the disease and how different treatments work. Participants will provide blood and tissue samples and be monitored for years. The goal is to better understand the conditi…

This study aims to understand why some ROS1-positive non-small cell lung cancers stop responding to the drug entrectinib. Researchers will analyze tumor or blood samples from 38 patients who have already taken entrectinib as part of their regular care. By looking at the genetic c…

This study aims to find out what factors help predict whether CAR-T therapy will work well for people with relapsed or refractory large B-cell lymphoma. Researchers will look at patient characteristics, tumor features, and immune system changes in 80 participants. The goal is to …

This study looks at how different types of anesthesia affect cancer cells and recovery in 90 adults having colorectal cancer surgery. Participants are randomly assigned to receive anesthesia with opioids, fewer opioids, or no opioids at all. Researchers will measure markers of in…

This study watches about 1,852 people with esophageal cancer to see how often the cancer spreads to a specific lymph node near the windpipe. Doctors will also look for factors that raise the risk of this spread. The goal is to learn more, not to test a new treatment.

This study tests whether a special HER2-PET scan can predict if the drug T-DXd will shrink tumors in people with advanced breast cancer. About 100 participants with HER2-positive or HER2-low breast cancer will get the scan before starting T-DXd. The goal is to see if the scan can…

This study is creating a detailed database of 1000 people with a specific type of pancreatic cancer (KRAS-mutant). Researchers will track how long patients live and how long their cancer stays under control after receiving targeted therapy. The goal is to better understand which …

This study tracks 1,100 people with esophageal cancer to see how often the cancer spreads to lymph nodes behind the windpipe. Researchers will also look for factors that raise the risk of this spread. The goal is to better understand the disease and guide future treatment decisio…

This study explores whether age-related differences in blood components can predict how well breast cancer treatment works. Researchers will compare blood samples from younger and older women with HR+HER2- breast cancer before and during therapy. The goal is to find blood markers…

This study looks at whether the bacteria in your gut can help predict how well a combination of immunotherapy and chemotherapy works for advanced stomach cancer. About 300 adults with metastatic or locally advanced stomach cancer who haven't had chemo or immunotherapy before will…

This study is testing whether a new blood test that looks for tumor DNA can detect the return of colorectal cancer earlier than standard methods. About 584 people who had surgery for early-stage colorectal cancer will be randomly assigned to either the new blood test monitoring o…

This study looks at whether a person's mental state—like anxiety or depression—can influence how well immunotherapy works for triple-negative breast cancer. About 120 women will receive standard treatment, complete psychological surveys, and give blood and saliva samples. Researc…

This study looks at whether a blood test that detects tumor DNA (ctDNA) can help doctors monitor how well treatment is working in people with stomach cancer. About 600 participants will provide blood samples before and during treatment to see if changes in ctDNA levels predict re…

This study follows 3000 adults aged 40 and older to see if certain genetic types of H. pylori bacteria raise the risk of stomach cancer. Participants will have initial and follow-up exams over 3 to 10 years. The goal is to identify high-risk bacterial strains to improve cancer pr…

This study aims to find out which types of HPV are most common in anal cancer patients in China and how the disease affects people. Researchers will collect samples and health data from 300 patients across multiple hospitals. The goal is to better understand the virus's role and …